Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Merck & Co., Inc. (CIK 310158) reported $349.4M across 12 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: MRNA ($117.3M, 33.56%), PSNL ($89.5M, 25.60%), KYMR ($64.3M, 18.40%), TRDA ($22.0M, 6.28%), ($17.6M, 5.05%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MRNA | MODERNA INC | $117.3M | 33.56% | 2.3M | Hold |
| 2 | PSNL | PERSONALIS INC | $89.5M | 25.60% | 14.0M | Hold |
| 3 | KYMR | KYMERA THERAPEUTICS INC | $64.3M | 18.40% | 772,165 | Hold |
| 4 | TRDA | ENTRADA THERAPEUTICS INC | $22.0M | 6.28% | 1.7M | Hold |
| 5 | EIKON THERAPEUTICS INC | $17.6M | 5.05% | 1.7M | New | |
| 6 | AKTIS ONCOLOGY INC | $17.0M | 4.88% | 952,844 | New | |
| 7 | ALEC | ALECTOR INC | $7.6M | 2.18% | 3.5M | Hold |
| 8 | STRO | SUTRO BIOPHARMA INC | $6.8M | 1.94% | 272,351 | Hold |
| 9 | EVAX | EVAXION BIOTECH A/S | $4.5M | 1.29% | 1.2M | Hold |
| 10 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.8M | 0.52% | 93,414 | Hold |
| 11 | XLO | XILIO THERAPEUTICS INC | $891,309 | 0.26% | 105,982 | New |
| 12 | CARM | CARISMA THERAPEUTICS INC | $47,880 | 0.01% | 1.5M | Hold |
| 13 | NEUP | NEUPHORIA THERAPEUTICS INC | $40,810 | 0.01% | 10,027 | Hold |
| 14 | HURA | TUHURA BIOSCIENCES | $34,807 | 0.01% | 19,445 | Added |
| 15 | XLO | XILIO THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31